

No.	Particulars	UNAUDITED		AUDITED	
		9 Months ended 30/09/2007	31/12/2007	9 Months ended 30/09/2007	31/12/2007
1	Net Sales / Income from Operations	3,171.57	297.58	1,297.08	3,929.15
2	Other Income	149.30	0.00	107.52	0.00
3	<b>Total Income</b>	<b>3,320.87</b>	<b>799.52</b>	<b>1,292.08</b>	<b>4,031.68</b>
4	Total Expenditure / decrease in stock in trade	2,927.95	1,236.63	4,078.87	3,974.54
(a)	(Increase) / decrease in stock in trade	(50.66)	(43.15)	(93.72)	55.73
(b)	Consumption of raw materials	1,792.65	645.99	2,416.65	2,378.43
(c)	Staff cost	390.08	126.62	516.69	418.43
(d)	Depreciation	138.53	50.36	188.88	164.07
(e)	Other Expenditure	657.35	479.72	1,048.37	917.88
5	Interest	178.30	139.45	317.75	198.88
6	Exceptional Items	-	815.32	-	815.32
7	<b>Profit / (Loss) before taxation (3) - (4+5+6)</b>	<b>214.62</b>	<b>(1,394.89)</b>	<b>140.62</b>	<b>(1,180.26)</b>
8	Provision for Taxation - Current tax	23.90	11.10	(1.87)	35.00
-	- Deferred tax	-	(73.49)	-	(66.70)
-	- Fringe Benefit Tax	2.03	1.55	1.60	3.58
9	<b>Profit / (Loss) after taxation (7-8)</b>	<b>181.90</b>	<b>(1,334.04)</b>	<b>129.69</b>	<b>(1,152.14)</b>
10	Paid-up Equity Share Capital (Face value of Rs.10/-each)	350.04	350.04	349.54	350.04
11	Reserves excluding revaluation reserves	-	-	-	2,784.68
12	Basic & Diluted EPS (Rs.) (Not Annualised)	4.40	(38.36)	3.47	(33.98)
(a)	Basic EPS	4.04	(38.36)	3.37	(33.98)
(b)	Diluted EPS	-	-	-	(33.98)
13	Aggregate of Public shareholding:				
(a)	Number of shares	28,314,149	28,417,595	28,374,028	28,417,595
(b)	Percentage of shares	80.89%	81.18%	81.18%	81.18%

**Notes:**  
1 The above results of the Company, both stand alone and consolidated, were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on March 7, 2008

2 During the quarter:  
a) Onco Therapies Limited was acquired from Quantum Life Sciences Private Limited, a wholly owned subsidiary of the Company.  
b) The Company, consequent to its decision to exit from specialty chemicals business, sold its investment in its wholly owned subsidiary, Sequent Scientific Limited for Rs.55.20 Million.

3 Raycom Limited, a Cyprus company became a wholly owned subsidiary of the Company on January 1, 2008

4 The Company entered into an agreement with Onco Therapies Limited to transfer its Oncology manufacturing facility, which is in the process of being setup, for a consideration amounting to USD 32.50 Million (Rs.1,280.50 Million)

5 Exceptional Item:  
a) The Company recognised permanent diminution in its investment in Strides Inc, USA, a subsidiary, due to changed regulations which made the operations of the facility unviable. Accordingly, investment value of Rs.798.10 Million has been written down in the books of account as at December 31, 2007. The manufacturing activity has been shut down and opportunity for sale of the assets is being explored.

b) The Company assessed its investment value in Arcolab S.A.S, Switzerland for diminution and estimated permanent diminution in value of investment to the extent of Rs.17.22 Million.

6 On October 30, 2007, the Company granted 200,000 Employee Stock Options under the Strides Arcolab ESCOP 2006 scheme to certain eligible employees.

7 The Board has not recommended any dividend for the year

8 The Company operates exclusively in the Pharmaceuticals business segment and as such there is no reportable segment information as per Accounting Standard 17.

9 Investor grievances received and disposed off during the quarter ended December 31, 2007

a) Pending complaints at the beginning of the quarter - Nil b) No. of Complaints received - 21  
c) Complaints disposed - 21 d) Complaints unresolved - Nil

10 Previous years / period's figures have been recast / restated wherever necessary to conform to the current year's/period's classification.

Bangalore  
March 7, 2008

For and on behalf of the Board  
Arun Kumar  
Vice Chairman & Managing Director

**AUDITED CONSOLIDATED FINANCIAL RESULTS**  
FOR THE YEAR ENDED DECEMBER 31, 2007

RS. in Million

No.	Particulars	AUDITED	
		Year ended 31/12/2007	Year ended 31/12/2006
1	Net Sales / Income from Operations	7,256.12	7,429.84
2	Other Income	1,392.36	1,172.14
3	<b>Total Income</b>	<b>8,648.48</b>	<b>7,601.98</b>
4	Total Expenditure / decrease in stock in trade	7,878.56	6,578.60
(a)	(Increase) / decrease in stock in trade	(617.40)	19.15
(b)	Consumption of materials	4,210.18	3,256.32
(c)	Staff cost	1,625.47	1,241.44
(d)	Depreciation & amortisation	377.14	336.18
(e)	Other Expenditure	2,262.17	1,575.51
5	Interest	596.76	408.03
6	Exceptional Items	539.85	-
7	<b>Profit / (Loss) before taxation (3) - (4+5+6)</b>	<b>(345.69)</b>	<b>655.35</b>
8	Provision for Taxation - Current tax	119.23	105.88
-	- Deferred tax	(67.39)	61.14
-	- Fringe benefit tax	3.98	6.51
9	<b>Profit / (Loss) after taxation (7-8)</b>	<b>(516.54)</b>	<b>491.82</b>
10	Less: Share of Profit / (Loss) of Minority Interest	15.27	(89.53)
11	Add: Share of Profit in associate	0.06	-
12	<b>Consolidated Profit / (Loss) after Minority Interest &amp; share from Associate</b>	<b>(501.21)</b>	<b>402.29</b>
13	Basic & Diluted EPS (Rs.)	(15.57)	11.51
(a)	Basic EPS	(15.57)	10.16
(b)	Diluted EPS	-	-

**SEGMENT REVENUE RESULTS AND CAPITAL EMPLOYED**

No.	Particulars	Year ended 31/12/2007		Year ended 31/12/2006	
		Revenue	Capital Employed	Revenue	Capital Employed
1	<b>Segment Revenue</b>				
a)	Pharmaceuticals	6,932.11	7,013.09	6,932.11	7,013.09
b)	Contract Research And Manufacturing	425.64	505.82	425.64	505.82
<b>Total</b>		<b>7,357.75</b>	<b>7,518.91</b>	<b>7,357.75</b>	<b>7,518.91</b>
2	Less: Inter Segment Revenue	101.87	85.63	101.87	85.63
	<b>Net Sales / Income from Operations</b>	<b>7,255.88</b>	<b>7,433.28</b>	<b>7,255.88</b>	<b>7,433.28</b>
	<b>Segment Results</b>				
	Profit / (Loss) before interest & tax	(631.13)	869.87	(631.13)	869.87
a)	Pharmaceuticals (including share from Associate)	(23.46)	34.81	(23.46)	34.81
b)	Contract Research And Manufacturing	(607.67)	904.66	(607.67)	904.66
<b>Total</b>		<b>(586.76)</b>	<b>406.05</b>	<b>(586.76)</b>	<b>406.05</b>
	Less: 1. Interest charges	-	-	-	-
	2. Other unallocable expenditure net of unallocable income	(852.74)	(188.70)	(852.74)	(188.70)
	<b>Total Profit / (Loss) before tax and allocation of minority share</b>	<b>(345.69)</b>	<b>655.35</b>	<b>(345.69)</b>	<b>655.35</b>
3	<b>Capital Employed</b>				
a)	Pharmaceuticals	10,454.90	7,787.94	10,454.90	7,787.94
b)	Contract Research And Manufacturing	10,454.90	586.26	10,454.90	586.26
<b>Segment Capital Employed</b>		<b>10,454.90</b>	<b>8,376.20</b>	<b>10,454.90</b>	<b>8,376.20</b>